Communicating About Nicotine Reduction in Cigarettes
Launched by GEORGIA STATE UNIVERSITY · Jan 16, 2025
Trial Information
Current as of July 04, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how messages about reduced nicotine cigarettes, along with the use of very low nicotine cigarettes (VLNCs), can change smoking habits and attitudes among adult smokers. The researchers want to find out if smokers who receive these messages while using VLNCs will smoke fewer cigarettes compared to those who only use VLNCs without the messages. The study will focus on different groups of smokers, including those experiencing significant psychological distress and those with lower income levels.
To participate, individuals must be at least 21 years old, currently smoke regularly, and be willing to try new types of cigarettes. They should be comfortable communicating in English and be available for the study's duration. Participants will complete an initial survey, be randomly assigned to either the group that receives VLNCs with messages or the group that receives VLNCs without messages, and attend weekly visits for follow-up surveys and breath tests. It’s important to note that pregnant or breastfeeding individuals and those living with another study participant cannot join. This trial aims to provide valuable insights into how effective messaging can help reduce smoking.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 21+ years
- • Current smoker (self-report as having smoked 100 cigarettes in their lifetime and currently smoking on 27+ days out of past 30, expired breath carbon monoxide \[CO\] ≥6ppm to assess regular smoking)
- • Can speak, read, and write in English
- • Available for period of study
- • Willing to try novel research cigarettes
- Exclusion Criteria:
- • Pregnancy or lactation
- • Member of the same household as a study subject
- • Unwilling to use research cigarettes as part of the trial
About Georgia State University
Georgia State University is a leading research institution dedicated to advancing knowledge through innovative clinical trials and studies. With a strong emphasis on public health and community well-being, the university leverages its multidisciplinary expertise to conduct rigorous research aimed at addressing pressing health challenges. As a sponsor of clinical trials, Georgia State University fosters collaboration among researchers, healthcare professionals, and community partners, ensuring ethical standards and scientific integrity are upheld throughout the research process. Its commitment to translating research findings into real-world applications positions the university as a key contributor to the advancement of medical science and improved patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Atlanta, Georgia, United States
Atlanta, Georgia, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported